F Facts, NTC Aspiration - Annals of Internal Medicine, 1999 - Am Coll Physicians The incidence of adenocarcinoma of the esophagus and gas- tric cardia has increased sharply
in the last decade. Because the reasons for this increase are unclear, researchers in Sweden
conducted a nationwide case–control study to determine the epidemiologic association ... Related articles
M Etiology - pathways - journals.lww.com D i ü u News hour in young, healthy men and at ap- proximately 9 ng/ml in young women. Absorption
is decreased by approxi- mately 25% when administered with food, with a mean delay in time
to peak concentration of 15 minutes. Plasma concentrations of alosetron increase ... Related articles
M Kirsch - The American journal of gastroenterology, 2000 - ncbi.nlm.nih.gov 1: Am J Gastroenterol. 2000 Jun;95(6):1588-9. Comment on: Am J Gastroenterol.
1999 Oct;94(10):3010-4. Re: Daniel et al.: liver biopsy without clear indication or
informed consent. Kirsch M. Publication Types: Comment; Letter. ... Related articles - BL Direct - All 5 versions
G Bodemar, G Ragnarsson - Läkartidningen} - ltarkiv.lakartidningen.se 15–25 procent av västerländsk befolkning har irriterade tarmens syndrom. De flesta läkare har
en god uppfattning om när diagnos kan ställas, och uppföljande studier visar att dok- torn oftast
får rätt [1]. ... Klinisk definition av irriterade tarmens syndrom Så länge diagnostiska ... Related articles - View as HTML - All 2 versions
M Plebani, D Basso - The Lancet, 1999 - Elsevier We have applied the same test to 45 patients (18 men, 27 women, aged 20–77) undergoing
upper gastrointestinal endoscopy for the first time and who had no previous treatment for H pylori
infection or treatment with any antibiotic or proton-pump inhibitor or bismuth-containing ... Cited by 11 - Related articles - All 3 versions
M Treating - clinicalevidence.bmj.com H pylori eradication treatment, possibly avoiding, or delaying, the need for radical surgery,
radiotherapy, or chemotherapy. ... We found no systematic review or RCTs. ... We provide
up-to-the-minute updates for this review so you always have the latest evidence. Related articles - All 2 versions
M Lièvre - BMJ: British Medical Journal, 2002 - pubmedcentral.nih.gov On 9 February 2000 alosetron (marketed as Lotronex by GlaxoSmithKline), a type 3 serotonin
(5-HT3) receptor antagonist, was approved by the US Food and Drug Administration (FDA) for
the treatment of patients with irritable bowel syndrome, a benign though unpleasant ... Related articles - All 3 versions
R Horton - The Lancet, 2001 - Elsevier Lotronex was licensed by the US Food and Drug Administration (FDA) in February, 2000. By
November, GlaxoWellcome had voluntarily withdrawn Lotronex from the market. At least five
people had died after taking the drug. Yet many within the FDA's leadership now want to ... Cited by 52 - Related articles - BL Direct - All 6 versions
